Remember all those articles about whether venture was overvalued? With blinding speed, they now seem quaint. Bluntly stated, most venture backed companies are in a fight for survival. Although certain areas of life sciences may do somewhat better, I think the impact will be widely felt. Complicating the fight is the fact that no one…

Retroactive pay-to-plays are not common in a rising market but are likely to become very common over the next year or two. When inside investors “pass the hat” for the next funding round, those investors unable/unwilling to fund their pro-rata could confront some very harsh consequences. Even for companies that already have pay-to-play clauses in their…